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MYO1Fhe pathogenesis of hearing loss is well established: ﬁve genes encoding
unconventional myosins and two genes encoding nonmuscle conventional myosins have so far been
described to be essential for normal auditory function and mutations in these genes associated with hearing
impairment. To better understand the role of this gene family we performed a mutational screening on two
candidate genes, MYO1C and MYO1F, analyzing hundreds of patients, affected by bilateral sensorineural
hearing loss and coming from different European countries. This research activity led to the identiﬁcation of
6 heterozygous missense mutations in MYO1C and additional 5 heterozygous missense mutations in MYO1F.
Homology modelling suggests that some of these mutations could have a potential inﬂuence on the structure
of the ATP binding site and could probably affect the ATPase activity or the actin binding process of both
myosins. This study suggests a role of the above mentioned myosin genes in the pathogenesis of hearing loss.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionMyosins are actin-basedmolecular motors, ubiquitously expressed
as multiple isoforms in all eukaryotic cells. Almost all myosins known
to date are composed of one or two conserved heavy chains, formed
by the N-terminal globular motor domain, with ATP- and actin-
binding sites, of a “neck” with one or more IQ motifs (that binds
calmodulin or calmodulin-like chains) and of at least one variable light
chain responsible for the speciﬁc function of the myosin [1–3].
Myosins are commonly classiﬁed into conventional myosins, which
are similar in the head sequence and structure to muscle myosin, and
unconventional myosins whose sequence is similar in the head but
different in the tail. During the past years, considerable attention has
been paid to the role of unconventional myosins in inner ear sensory
hair cells. As a matter of fact, several myosins have been shown to play
a relevant role in sound detection and signal transmission processes
occurring in sensory hair cells of the cochlea [4,5]. Five genes encoding
unconventional myosins (Ia, IIIa, VI, VIIa and XVa), and two genes
encoding nonmuscle conventional myosins (MYH9 and MYH14) are
essential for normal auditory function and mutations in these genes
have been associated with hearing impairment [6–10]. Myosin VIIAni).
l rights reserved.has been shown to be responsible for Usher syndrome type IB [11] and
of a dominant form of nonsyndromic deafness DFNA11 [12,13], while
its role in causing recessive forms of nonsyndromic deafness (DFNB2)
is still controversial [14–16]. Mutations in MYO6 have been described
in human and mice, with a recessive inheritance in the Snell's waltzer
mouse [17], and both autosomal dominant and recessive patterns in
humans (DFNA22 and DFNB37) [18,19]. MYO15A is mutated in human
DFNB3 and in mouse shaker-2 [20,21]. Recently, mutations in MYO3A
and in MYO1A have been shown to cause non syndromic forms of
recessive hearing loss, DFNB30 and DFNB48, respectively [8,9].
Recent data suggest that MYO1C and MYO1F, encoding unconven-
tional myosins expressed in the inner ear, may represent good
candidates for hereditary hearing loss in mammals. To evaluate
MYO1C and MYO1F as candidate genes for deafness, we analyzed 450
subjects by mutational screening using denaturing high-performance
liquid chromatography (DHPLC) and direct sequencing of electro-
phoretically abnormal fragments.
2. Materials and methods
2.1. Sample
Samples included 450 subjects showing bilateral sensorineuronal
hearing loss, without any feature, clinical sign and/or symptoms of
known syndromes (visual defects, facial appearance, skin
Table 1
Primers and annealling temperature of MYO1C
Amplicon Size bp Primer sequence (5′–3′) Annealing temperature
1 326 F: GTTCCCTCTCAGTCCCACAG 60 °C
R: GGTGCACCT TGGTGTCTCTT
2 290 F: CGGATTTCTCCATGTTGGTC 60 °C
R: TGCGACATTCATCTCTGGTC
3 332 F: TCGACTCCCACAAGAGGACT 60 °C
R: ACTGGCACTGGGCTTCTCT
4 277 F: GGGCAGCAGTAGCTACAAGG 58 °C
R: GCTTTGTTTGACTGCTGGAA
5 466 F: GTGGGCTGTTTTCCCAGTC 58 °C
R: AGATTTTGGGGGTGTGACAG
6 418 F: TCTGCTAGTTGCCCTCTTGG 60 °C
R: AGGGGAGTGATGGGAGTAGG
7 446 F: AGGCTCTGTGGCATTCATCT 58 °C
R: ATGAGAGGCTGGAGGACAGA
8 468 F: TGTTTCTCACCTCCTGTGCTC 60 °C
R: ACGGAGAAGGGGGACATC
9 230 F: CTCTGACCTGTCCCCCATAC 58 °C
R: GTGGCTGGTGTTTTGTGATG
10 366 F: GCTGGTTCCTGCTCCTGA 60 °C
R: GTGCAGAGCTGTGGGCTATC
11 235 F: TGTCCTGCCTGTCCCTGT 62 °C
R: GCTCACACGCGTTCACAC
12 434 F: AGCAGCTTTAGCCCAGCTC 60 °C
R: GACCTAGGGGCTCCTACCC
13 408 F: GTGCCCAGAGAAAGCTGATT 60 °C
R: GGAGTGACTTCCCTGCTTCC
14 280 F: TTGGTTCCTTCAGCCACTCT 58 °C
R: TGTCGTGGAGACCACAGATG
15 459 F: CCATGGTAAGAAGATAGAGTTCAGC 60 °C
R:CCGAAGAAATCAGACCCTTC
16 184 F: CGATGTCTTCAGAGGGAAGGGAAGG 60 °C
R: TCCACTTCCTCATCCTCACC
17 392 F: GGAGGCTGTCTCAGGTCCTA 60 °C
R: TCAGCTCTCAGGCAGTAGCA
18 387 F: GAGAGCTGAAGGCAGGTCAG 58 °C
R: CCTCCCCATCCATGAAAAG
19 447 F: GGGGGTTCCTCAAGTTCTG 60 °C
R: AGGAAGGCTTGGCTATCACA
20 358 F: CGAGACCCCATTCTCCATAA 58 °C
R: CCTGGCTTTCCTATTGCTGT
Table 2
Primers and annealling temperature of MYO1F
Amplicon Size bp Primer sequence (5′–3′) Annealing temperature
1 387 F: GAGATGGGGAAGGAGGAATG 62 °C
R: TGTCACCACTTGGTGCTCTC
2–3 385 F: CACACGACCCTTAACCATCC 62 °C
R: GATTGGGAGTTTCAGGCAAA
4–5 399 F: CCACTGATCATTTATTCCTCCA 64 °C
R: TGGGTGTGTGTGTAGAAAGGTC
6 247 F: TCATAAGACCCATCCCCAAC 62 °C
R: AGGTGGTGCTCCCTCTCC
7 231 F: CCAGGCAAGCACCAGATG 60 °C
R: GTTTCTGGGGCTGAGGTCT
8 236 F: GGATTCACGGCACAGTTTCT 60 °C
R: GCTAGGAGGACGCAGTTCAC
9 291 F: ACCAACTGTCCCATTTTTGC 58 °C
R: AATGTTTGTGACCCCAGAGC
10–11 389 F: ATGCCCACTGACTTCCTGTC 60 °C
R: AGGGATCCTCATGGTCCTTC
12 240 F: GATGGAGAAGGGGAGAGGAC 60 °C
R: TGAGTCTGGAAGATGAGGGG
13 298 F: CCTCCCTCCCCTAATCTCTG 60 °C
R: CTGTGCCTCCTCGCAGA
14 223 F: CCAGGTTTCTCAGTCCCTCA 60 °C
R: CCATCTTACCCAGAACTGCC
15 207 F: TGGAGGAAGAGTACCCGAAA 60 °C
R: GCTGAGTTCCACCCTACCTG
16 247 F: CAGAGGGTCCCATCTCTGTG 60 °C
R: AGACACCTCCCTGACCTCCT
17–18 425 F: GAGGGGACTCAGCCTACCC 58 °C
R: GGAGAGGGGAAGAGAGAGAAA
19–20 398 F: GAGGGGACTCAGCCTACCC 64 °C
R: AGTGTGTTTGAGGGACAGGC
21 241 F: GATGGAGAAGGGGAGAGGAC 58 °C
R: TGAGTCTGGAAGATGAGGGG
22 388 F: GCTGACCCTTCCCTAAATCC 60 °C
R: ACCAGCGAGAGTTGGGTG
23 246 F: CCCCAAGCTTTCTTCTCTCC 58 °C
R: TAAGAGTGGACGAAGGCCAG
24 214 F: CGGAGCCTCAGAATGGACTA 58 °C
R: ATTCCCTTGTCTGTTGTGGG
25 347 F: GAAGCCAAGTCCTCCTCAAA 60 °C
R: GTGACTCAAACCCCCTGTG
26 244 F: CTGTGACTCAAACCCCCTGT 58 °C
R: GGTGAGGGGAGTGGTAAGAA
27 246 F: AGGCATGAGAGCTTTCTCCA 60 °C
R: TTTACCTGGGCTGCAATAGC
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were: absence of the most common mutations within GJB2, bilateral
sensorineural hearing loss and normal tympanometric evaluation.
Hearing function was evaluated using standard audiometric instru-
mentations according to worldwide accepted guidelines and proto-
cols. The sample set includes cases with a variable degree of hearing
loss, ranging from mild to profound (according to ASHA classiﬁca-
tion) and with a variable age of onset, from congenital to late onset.
In all cases, vestibular data were obtained by clinical examination
and routine vestibular tests (one or more of the following: caloric,
rotatory, optokinetic, swinging torsion, statokinesimetric, and
vestibulo-vegetative). Familial records were also available. The
majority of patients came from central and southern Italy (200),
while 140 were from Spain, 60 from Belgium, and 50 from Israel. All
patients have been recruited trough medical genetics diagnostic
services. For Italian patients informed consent was obtained
according to our national rules and laws on genetic tests and
privacy [i) art.10 and 22 of the Italian law 196/03 on privacy and
following updates published on the Gazzetta Ufﬁciale n.65 of 19
March 2007, ii) National authorization n.2-2004 to conduct research
activities on genetics, iii) Government authorization to referral
research centers (an IRCCS in our National Health Care System) to
perform genetic tests 02-2007]. For samples coming from Spain,
Belgium and Israel consent form was obtained according to
respective national rules and laws. Peripheral blood was obtained
from all subjects, and DNA was isolated from blood leukocytes using
standard methods.2.2. Genetic analysis
A set of 20 and 22 primer pairs were designed to amplify MYO1C
and MYO1F, respectively (Tables 1 and 2). PCR fragments include the
coding regions and the splice sites. All amplicons were screened by
DHPLC, performed on a WAVE Nucleic Acid Fragment Analysis System
HSM (Transgenomic), according to supplier protocols. DHPLC data
analysis was based on a subjective comparison of sample and
reference chromatograms. PCR products that showed an abnormal
chromatographic proﬁle on DHPLC analysis were sequenced directly
on an automated sequencer (ABI 3130; Applied Biosystem, USA) using
the ABI-PRISM big-dye Terminator Cycle Sequencing Ready Reaction
kit (Applied Biosystem, USA). The possible pathogenicity of variants
was also assessed, evaluating the conservation of residues by multiple
sequence alignments of homologous proteins obtained with the WU-
BLAST algorithm. The presence of mutated alleles was tested on 200
normal chromosomes of individuals coming from the same geogra-
phical area of patients (100 healthy controls coming fromBelgium,100
from Italy and 100 from Spain).
2.3. Homology modelling
In order to understand the effects of themutations on protein level,
the structures of myosin-1c and myosin-1f proteins were built by
Table 3
MYO 1C mutations
MYO1C
Gene ID: 4641
Exon Nucleotide
variation
Amino acid
variation
Amino acid
conservationa
Effects of
variationb
4 476 CNT R156W + + + + + +
5 756GNA V252A + + + + +
7 1136GNA T380M + + + + +
15 2248CNA Q750K + + + n.d.
16 2469ANC K823N + n.d.
16 2491GNA E831K + + + n.d.
a + + + residue well conserved; + + residue partially conserved; + residue very
partially conserved.
b + + + very relevant; + + relevant; n.d. not determined.
Table 4
MYO 1F mutations
MYO1F
Gene ID: 4542
Exon Nucleotide
variation
Amino acid
variation
Amino acid
conservationa
Effects of
variationb
2–3 251CNT P84L + + + + + +
7 649ANT A217T + + + + +
13 1504ANG I502V + + + + +
15 1656GNC K552N + + n.d.
19–20 2296GNA D766N + + + n.d.
26 3080GNA R1027Q + n.d.
a + + + residue well conserved; + + residue partially conserved; + residue very
partially conserved.
b + + + very relevant; + + relevant; n.d. not determined.
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12–852) and myosin-1f (a.a. 9–733) have been modelled with the
program MODELLER (release 8v2) [22] using the crystallographic
structure of myosin-2 heavy chain (nonmuscle) from Dictyostelium d.
(PDB entry 1g8x, chain A) as a template. In the modelled region,
myosin-1c and myosin-1f share respectively 36% and 39% amino acid
identity with the sequence of the template myosin (sequence
alignments available on request). The ADP molecule co-crystallized
with the template myosin structure 1g8x has been retained in its
corresponding position also in the myosin-1c and myosin-1f models
to indicate the putative binding site of the ATP nucleotide phosphate
cofactor. This computational method has allowed prediction of the
effects of the mutations falling inside the modelled regions of myosin-
1c and myosin-1f.
3. Results and discussion
Variations detected inMYO1C andMYO1F are summarized in Table
3 and Table 4, respectively.
3.1. Myosin-1c
Six missense mutations, at heterozygous state, have been detected
in MYO1C gene. 5 of the affected residues are well conserved across
species. Variations R156W, V252A and T380M are located in the
myosin head domain, while Q750K is located in the third IQ domain;
K823N, E831K are located between the third IQ domain and the TH1
domain.
R156W is due to a CNT nucleotide change at position 467. It was
detected in a Spanish sporadic case (coming from Mallorca Isle)
affected by bilateral sensorineural hearing loss. In this mutation, an
arginine, a residue evolutionarily conserved and probably important
in ATP binding, is substituted with a tryptophan. Homology modelling
predicts that the R156Wmutationwould cause a strong change in the
physical–chemical properties of an amino acid that makes direct
contact with the ATP co-factor (Fig. 1A).
In an Italian patient with a moderate form of bilateral sensor-
ineural hearing loss, the mutational screening highlighted the
substitution 756GNA leading to the amino acid change V252A. The
evolutionary conserved Val 252 interacts with a group of amino acids
that includes Val 145, Ala 148 and Gln 207, contributing to stabilize the
arrangement of α-helices nearby the binding site of ATP (Fig. 1B).
Mutations involving Val 252 are therefore expected to interfere with
the binding of ATP.
MutationT380M is due to aGNAnucleotide change at position1136;
it was detected in Spanish subject with a family record of progressive
bilateral sensorineural hearing loss and an autosomal dominant
pattern of inheritance; the age of onset was 18. The T380M mutation
implies the replacement of a polar with a non-polar amino acid in a
protein site characterized by tight packing of secondary structureelements. The effects of this mutation are important since T380
interacts with amino acids that contribute to form α-helix directly
involved in the binding of ATP (Fig. 1C). R156W, V252A and T380M
mutations occur in the myosin head-like domain, and particularly in
sites of the protein that are relevant in ATP binding and/or in the
conversion of the chemical energy of this co-factor into mechanical
energy, which is fundamental in the myosin–actin interaction.
The Q750K mutation is due to a nucleotide change CNA at position
2248, with a glutamine/lysine substitution and was detected in a
Spanish patient affected by bilateral sensorineural hearing loss.
K823N, with nucleotide change 2469ANC, was observed in two
members of a family: a 10 years old girl with a bilateral mild hearing
loss and a 7 years boy affected by moderate/severe bilateral
sensorineural hearing loss. The age of onset was approximately
3 years old. Biological samples of their parents were not available.
Finally, E831K was detected in a Spanish patient affected by
bilateral sensorineuronal hearing loss: this variation, characterized by
a nucleotide change GNA at 2491 position, causes a glutamic acid to
lysine substitution. Mutation Q750K lies in the third IQ domain and
might affect the calmodulin binding function of the protein. Genetic
studies have shown that the region of interaction between myosin-1c
and PHR1 is located in the c-terminal region of myosin-1c (a.a. 762-
1028): mutations K823N and E831K could affect myosin-1c and PHR1
interaction.
In conclusion, 5 of the six alleles identiﬁed in MYO1C affect
residues highly conserved across species and for 3 of them bioinfor-
matic analysis strongly suggest a relevant functional role.
3.2. Myosin-1f
ForMYO1F, six missense variations have been detected, each one at
heterozygous state. Five of these amino acid changes involve
evolutionary highly conserved residues. The missense mutation
P84L was detected in a patient coming from Belgium; it is due to a
CNT nucleotide change at position 251, near the ATP-binding site
(relative to ATG, designated +1), with a proline/glutamic acid
substitution. Pro 84 makes direct contact with groups of surrounding
residues (Asp 20 carboxylic group, Phe 47 amide carbonyl group, and
Tyr 49 hydroxyl group). In addition, Pro 84 is also solvent-exposed,
which is a common feature for proline residues. The P84L mutation
implies replacement of Pro 84 with a leucine, a residue characterized
by a high tendency to locate away from the solvent. This mutation is
likely to cause a local structural destabilization and inﬂuencing the
nearby binding site of ATP (Fig. 1D).
Mutation c.649ANT was detected in an Italian patient with a
moderate form of sensorineural hearing loss. This nucleotide
variation is located in exon 9 and causes the substitution of the
alanine at position 217 with a threonine (A217T). Ala 217 is partially
conserved in the evolutionary scale and is involved in hydrophobic
interactions with the side chains of Leu 213 (one of the two δ-
Fig.1.Homologymodelling of the sites of mutation falling within the head domain of myosin-1c andmyosin-1f obtained using the crystallographic structure of myosin-2 heavy chain
(nonmuscle) from Dictyostelium d. (PDB entry 1g8x, chain A) as a template. Represented are the protein backbone (green ribbon-like structure), the amino acid site of mutation
(sticks with red surface), sets of selected amino acids (sticks with cyan surface) showing critical interactions with the mutated residues, and the ADP ligand (stick representation)
used to evidence the putative site of binding of the nucleotide phosphate co-factor. Details of myosin-1c structure in proximity of the mutating residues R156, V252 and T380 are
shown in panels A, B and C, respectively. Details of myosin-1f regions containing the mutated residues P84, A217 and I502 are shown in panels D, E and F, respectively.
30 C. Zadro et al. / Biochimica et Biophysica Acta 1792 (2009) 27–32carbon atoms), Gln 221 (the β-carbon atom) and Leu 227 (one of the
two δ-carbon atoms). The A217T amino acid change introduces a
threonine containing a polar side chain that cannot properly
replicate the hydrophobic interactions of the smaller and apolar
alanine residue. This mutation is expected to introduce an alteration
in a region of the protein that is also characterized by tight
interactions between secondary structure elements that are close to
the ATP binding site (Fig. 1E).
I502V and K552N are two missense mutations detected in
patients coming from Belgium and affected by mild to moderate
bilateral sensorineuronal hearing loss; these variations are due to an
ANG and CNG change, at positions 1504 and 1656, implying anisoleucine/valine and a lysine/asparagine substitution respectively.
These amino acids are located near the actin-binding sites of
myosin-1f. Ile 502 is part of β-sheet in the head of myosin-1f and
contributes to stabilize the protein structure through its hydro-
phobic interactions with Val 444, Leu 447 and Ile 448 residues
located on a neighbouring α-helix (Fig. 1F). The I502V mutation may
disrupt this set of interactions interfering with the binding of ATP.
The P84L, A217T and I502V mutations occur close to the ATP
binding site in the myosin head-like domain and might interfere
with the correct binding of the co-factor.
D776N is a missense mutation due to a GNA nucleotide change at
position 2296, in the TH1 domain and leads to a substitution of an
31C. Zadro et al. / Biochimica et Biophysica Acta 1792 (2009) 27–32aspartic acid with an asparagine. Aspartic acid is a residue highly
conserved and probably functionally important. It was detected in a
Spanish patient affected by bilateral sensorineural hearing loss. It
segregates within the family since it was inherited from the affected
father and also transmitted by the proband to the affected daughter
but not to the healthy one (dominant patter of inheritance). It was also
detected in a normal hearing member of the family; this information
could exclude its pathogenic role, even if we cannot discard the
hypothesis that this subject can manifest a hearing impairment in the
future.
Finally, R1027Q was detected in a Spanish patient affected by early
onset progressive sensorineuronal hearing loss. This variation is due
to a GNA nucleotide change at position 3080; arginine 1027 is located
between the TH1 and SH3 domains. For this variation a pathogenic
role was excluded since it wasn't detected in the other affected
members of the probands family.
Thus, summarizing, 5 alleles affect residues conserved across
species, and prediction by homology modelling suggest a role for 3 of
them.
4. Conclusions
The pathogenic role of more than 40 genes has already been
described for hearing impairment. Within this heterogeneous group
of genes, 7 belong to myosin superfamily and explain both syndromic
and nonsyndromic forms. Expression, functional data and involve-
ment in hearing physiology suggest that other members of the myosin
superfamily could contribute to hearing loss. Since both MYO1C and
MYO1F are known to be expressed in cochlea and since MYO1F is
located in DFNB15, they can be considered good candidate genes for
nonsyndromic hearing loss.
Here we report the identiﬁcation of 11 heterozygous missense
mutations in MYO1F and MYO1C, both clearly expressed in inner ear,
in patients affected by bilateral sensorineuronal hearing loss.
MYO1C is a member of the family of unconventional type 1
myosins, characterized by the presence of the head domain (or motor
domain), three or four IQ domains and the TH1 domain (or tail
domain) at the C-terminus; the tail domain is rich in basic residues
which allow interactions with negatively charged membrane phos-
pholipids. Myosin-1c plays an essential role in adaptation of hair-cell
mechano-electrical transduction [23]. Recent experiments conﬁrmed
that myosin-1c is a component of the hair cell's adaptation-motor
complex, directly or indirectly interacting with other components of
the transduction apparatus to mediate slow adaptation [24].
Furthermore, myosin-1c has been proposed as amotor protein that
sets a resting tension on the tip link and the channels during fast
adaptation processes [25–27]. Moreover, recent data indicate that
myosin-1c interacts in vitrowith three othermolecules proposed to be
important for transduction: cadherin 23 (CDH23), phosphatidylinosi-
tol 4,5-bisphosphate (PIP2) [28] and PHR1, an integral membrane
protein [29].
The six missense mutations here reported suggest a pathogenic
role of myosin-1c gene in hearing loss. The homology modelling
proposes that mutations located in the head of myosin-1c have a
strong inﬂuence on its functionality: they are predicted to affect sites
of the protein relevant in ATP binding and/or in the conversion of the
chemical energy of this co-factor into mechanical energy. Instead, the
other missense mutations are located in IQ3, a domain, as suggested
by Phillips et al. [28], involved in the regulation of myosin-1c activity
by Ca2+ and in calmodulin binding, or in the region of interactionwith
PHR1. As hypothesized by Etournay et al. [29] PHR1 and myosin-1c
form a complex acting as elastic molecular cross linker that contribute
to and modulate the membrane tension in the slow adaptation
process: the increasing of the stereociliar Ca2+ concentration through
the open MET channels leads to the dissociation of myosin molecules
from actin ﬁlaments, decreasing the MET channel open probability.Summarizing, for MYO1C, all the mutated alleles described in this
study can modify the adaptation process in which myosin-1c and
PHR1 have an important role: a) mutations in the head of the protein
could modify the conversion of the chemical energy of this co-factor
into mechanical energy or the actin binding process; b) mutation in IQ
motifs could change the regulatory function of Ca2+ or calmodulin on
the myosin-1c activity; c) mutations in IQ4 or in the tail of the protein
could interfere with the correct assembly and function of PHR1-
myosin complexes. Other members of the transduction apparatus
have been shown to be involved in hearing loss: mutations in CDH23,
Harmonin, PCDH15, MYOVIIA, PMCA2 have been shown to cause Usher
Syndrome or autosomal forms of Hearing loss (see hereditary hearing
loss homepage at http://webh01.ua.ac.be/hhh/); mutations in MYO1C
suggest that proteins of the transduction apparatus have a key role in
the sensorineural forms of hearing loss.
Regarding myosin-1f, very limited information is available.
MYO1F is expressed in the cochlea and maps to chromosome
19p13.3–13.2 where is located the DFNB15, an autosomal recessive
nonsyndromic deafness locus [30]. The amino acid sequence
suggests the presence of a head domain, a single IQ domain, the
TH1 domain and at the C-terminus an SH3 domain as mediator of
protein–protein interactions [31]. Kim et al. [32] demonstrated that
in mice, Myo1f is expressed predominantly in the mammalian
immune system, and it was hypothesized that this protein could
direct immune cell motility and innate host defence against
infection. MYO1F was selectively expressed in neutrophils and was
shown to be indispensable for both phagocytosis of bacteria and
their destruction: it inhibits exocytosis of integrin containing
granules in neutrophils, preventing excess of adhesion. Myosin-1f
deﬁcient neutrophils show a stronger adhesion to integrin ligands
[33]. Since the inner ear immune response seems to be basically
cellular [34], a possible affection of integrin mediated adhesion
related to myosin-1f defects could increase the susceptibility to
infections or could cause a neutrophil impaired response, leading to
auditory tissues damage due to reactive oxygen species. Homology
modelling showed that all mutations detected in the MYO1F head
can seriously affect ATP binding, probably by reducing or modifying
myosin-1f function. On the basis of the role of myosin-1f in the
mammalian immune system, we can assume that hearing loss in
these patients can be due to an increased susceptibility to infections
or to an abnormal neutrophilic response with the production of
reactive oxygen species (ROS) and the subsequent involvement of
proteolysis enzymes and antimicrobial proteins [32].
For bothmyosin-1c andmyosin-1f, mutations detected in the head
domain could have a potential inﬂuence on the structure of the ATP
binding site and could probably affect their ATPase activity, although it
cannot be excluded that mutations in the head domain might also
interfere with the actin binding process. Moreover, structural studies
on myosins suggest that the interaction with actin requires large
conformational changes that involve several residues, and no clear
identiﬁcation of all the amino acids composing the actin-binding
regions is available yet. For MYO1C mutations located in other
portions of the protein, we can hypothesize a modiﬁcation of the
regulatory function of Ca2+ or calmodulin on the myosin-1c activity or
that of PHR1 interaction.
In conclusion, a) both genes are expressed in the inner ear and thus
have been selected as good candidates; b) mutants have been detected
at the heterozygous state in hearing impaired people but not in
normal controls; c) the vast majority of the alleles here described
affect residue highly conserved across species; d) modelling homol-
ogy, whenever applied, strongly suggest a functional role of mutants;
e) whenever possible a segregation within families was shown. We
cannot rule out the possible presence of rare recessive alleles or the
identiﬁcation of carriers in which the cause of hearing loss is
attributable to other genes, but all our ﬁndings suggest to exclude a
mutational load and propose a possible causative role of the above
32 C. Zadro et al. / Biochimica et Biophysica Acta 1792 (2009) 27–32mentioned genes in hearing loss. Future studies will better deﬁne the
role of MYO1C and MYO1F mutants in causing hearing loss.
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